- Subscribe
- Log In More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- Basket
- Search More
Advanced search
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
Advanced search
- CloseMore
Main menu
- Latest content
- Current issue
- Archive
- Authors
- About
- Podcasts
- Subscribe
- Log in More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
- BMJ Journals
You are here
- Home
- Archive
- Volume 83,Issue Suppl 1
- AB1620-HPR CHANGE IN THE UTILITY OF ANTINUCLEAR ANTIBODIES (ANA) FOLLOWING THE IMPLEMENTATION OF ANALYTICAL REQUEST BASED ON PATIENT PROFILE
Email alerts
Article Text
Article menu
- Article Text
- Article info
- Citation Tools
- Share
- Rapid Responses
- Article metrics
- Alerts
Health Professionals in Rheumatology Abstracts
Publication Only
HPR Implementation and service evaluation
AB1620-HPR CHANGE IN THE UTILITY OF ANTINUCLEAR ANTIBODIES (ANA) FOLLOWING THE IMPLEMENTATION OF ANALYTICAL REQUEST BASED ON PATIENT PROFILE
- I. De la Morena Barrio1,
- P. Olivan2,
- L. C. Charca Benavente3,
- D. Bedoya Sanchis4,
- J. J. Sanmartín Martinez5,
- D. Fernandez-Lozano6,
- N. Costas Torrijo7,
- P. Trenor Larraz8,
- E. Rodriguez Borja9
- 1Hospital Clínico Universitario de Valencia, Rheumatology, Valencia, Spain
- 2Universidad de Valencia, Rheumatology, Valencia, Spain
- 3Hospital Clinico Universitario de Valencia, Rheumatology, Valencia
- 4Instituto de Investigación INCLIVA, Rheumatology, Valencia, Spain
- 5Hospital Clínico Universitario de Valencia, Rheumatology, Valencia
- 6Hospital Clinico Universitario de Valencia, Rheumatology, Valencia, Spain
- 7Hospital Clínico Universitario de Valencia, Rheumatology, Valencia, Spain
- 8Hospital Clinico Universitario de Valencia, Rheumatologu, Valencia, Spain
- 9Hospital Clínico Universitario de Valencia, Laboratory, Valencia, Spain
Abstract
Background: The diagnosis of autoimmune diseases has increased, reflected in a rise in the number of ANA determinations per year and referrals to the rheumatology service (RS) for the assessment of positive results. It was estimated that 70% of diagnoses are based on laboratory tests, but if the indication for ANA corresponds to a reasonable pretest probability, the likelihood of obtaining valuable post-test information increases, and vice versa. The indiscriminate request for ANA leads to system overload and increased expenses, undermining the value of the results.
Objectives: To compare the employability and cost of ANA determinations before and after the implementation of a tool for requesting analyses based on the patient’s clinical profile in Primary Care (PC).
Methods: Retrospective, longitudinal study where two study periods are established: the year 2021 (24-month follow-up) and the year 2023 (follow-up for the year 2023). The following data are collected: number of ANA requests from PC, number of referrals to RS due to positive results, patient profile, clinical manifestations for which tests are requested, final diagnosis, discharges, and follow-up time. The expenditure on ANA determinations, the appropriateness of the request in referred patients, and the changes in these parameters before and after the tool’s implementation in 2022 are analyzed.
Results: There is an upward trend in the number of ANA requests from PC from 2019 to 2021, with a rising expenditure trend of 2.28%. Subsequently, this trend is reversed (Table 1), calculating a savings, solely in ANA determinations, of 36,120.96 euros in 2022 and 2023.
View this table:
- View inline
- View popup
Table 1.
Trend of ANA request from PC.
In 2021, 134 patients were referred to RS due to positive ANA, at a time when there were 3 rheumatologists, and 123 in 2023, when there were 5, showing a decrease in the referral rate to rheumatologists, being 44.6 in 2021 and 24.6 in 2023. Table 2 presents the comparison of variables from patients referred to RS in both periods.
View this table:
- View inline
- View popup
Table 2.
Characteristics of patients referred to RS for ANA+.
Conclusion: The new tool has facilitated a reduction in expenses for ANA determinations and referrals to the RS, and improving pretest appropriateness for those referred to the RS. In 2023, the diagnosis of rheumatoid arthritis, other types of arthritis, and polymyalgia rheumatica decreased, aligning with three of the clinical profiles defined by the tool and adjusting suspicion-determination.
REFERENCES: NIL.
Acknowledgements: NIL.
Disclosure of Interests: None declared.
- Interdisciplinary research
- Diagnostic test
- Quality of care
- Autoantibodies
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Interdisciplinary research
- Diagnostic test
- Quality of care
- Autoantibodies
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens
Log in using your username and password
Read the full text or download the PDF:
Subscribe
Log in via Institution
Log in via OpenAthens